Xsolla Expands Mobile and Digital Distribution Solution Offerings and Adds an NFT Checkout to the Growing Set of Tools and Services for Developers
28.4.2022 11:06:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, announced today that it has expanded their mobile and digital distribution solutions to provide more opportunities for developers to launch and grow their games around the world. In addition, Xsolla has added a new checkout feature to help developers scale their brands by selling and distributing NFTs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005554/en/
XSOLLA EXPANDS MOBILE AND DIGITAL DISTRIBUTION SOLUTION OFFERINGS AND ADDS AN NFT CHECKOUT TO THE GROWING SET OF TOOLS AND SERVICES FOR DEVELOPERS (Graphic: Business Wire)
“Xsolla is committed to providing best-in-class services and support for developers worldwide to help them reach more players in more geographies,” stated Chris Hewish, President of Xsolla. “We continue to develop new features that target the key challenges of marketing, launching, and monetizing video games. We have more to come in 2022 that will keep our partners ahead of the constantly evolving game climate.”
Mobile Web Shop - New Features
As the expanding mobile landscape continues to lead global gaming revenue, Xsolla’s Web Shop for Mobile Games has added new features to help mobile developers to reach more players and to remain at the forefront of the mobile gaming revolution.
● Expanded Analytics
Developers can create a transparent funnel that will increase efficiency in bringing new players to their Web Shop. This will help developers understand the player experience online and determine where and how users engage with their game.
● Unique Promotions
This built-in component helps developers benefit from in-app purchases through their Web Shop. Within the online experience, developers can provide promotional offers and launch discount campaigns, promo code offers, and bonuses to boost sales and bring new players online.
● Subscriptions Management
To help developers sell a complete catalog of digital goods in their Web Shop, Xsolla added robust subscription features. This allows developers to gain and retain new customers, create loyalty, generate reliable revenue streams, and manage subscriptions with confidence.
For more information about the Xsolla Web Shop, visit: https://xsolla.com/solution/web-shop-for-mobile-games
NFT Checkout
Xsolla has created an NFT Checkout process to allow developers to quickly and securely add NFTs to their game economy. This feature enables players to make purchases using their preferred payment method. The developer handles the minting and the delivery of the NFTs, while Xsolla handles the checkout and in-game items distribution process.
For more details about NFT Checkout, visit: https://xsolla.com/solution/payments/nft-checkout
Digital Distribution Hub
Xsolla Digital Distribution Hub connects games to a global network of apps, internet service providers (ISPs), banks, and other channels to help developers reach players and gain revenue from every transaction. This new solution empowers gamers to discover and support their favorite games through an optimized multi-platform experience and allows them to pay how and when they want.
Developers can now benefit from increased market penetration and brand awareness through distribution channels, such as super apps, online banking apps and mobile carrier marketplaces. With the Digital Distribution Hub your game can reach a vast audience of new users, save on distribution costs, and boost overall revenue and engagement.
To learn more about Digital Distribution Hub, visit: https://xsolla.com/products/digital-distribution-hub
Xsolla will present these solutions and more at several upcoming events, including GamesBeat Summit 2022, Pocket Gamer Connects Seattle, Nordic Game Show, Pocket Gamer Toronto, China Joy, and gamescom, in the next six months. Register to meet up with the experts at Xsolla by visiting: https://xsolla.com/events.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005554/en/
Contact information
Derrick Stembridge
Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom